You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Julia Naftulin Every time Julia publishes a story, you’ll get an alert straight to your inbox!

On June 21, the U.S. Food and Drug Administration (FDA) approved Vyleesi, a libido drug being hailed as the new “female Viagra.” On its surface, the move seems like a win for women’s sexual health—but ...

Two weeks ago, the Food and Drug Administration (FDA) approved Vyleesi (bremelanotide), a first-in-class injectable treatment indicated for hypoactive sexual desire disorder (HSDD) in pre-menopausal ...

Vyleesi is only the second drug to be approved for women with low sexual desire. We’ve long seen advertisements for drugs like Cialis or Viagra, which help to improve sexual performance in men with ...

Pop culturally, female sexual desire is treated as the holy grail: oft-sought, oft-imitated, oft-worshipped and oft-misunderstood. But outside of Hollywood writers’ rooms, the holy grail does not ...

The U.S. Food and Drug Administration today approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. “There are women who, for ...

VYLEESI is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women who have not gone through menopause, who have not had problems with low sexual desire in the ...

Addyi and Vyleesi are medications for boosting sexual desire in women. Addyi is taken daily at bedtime, while Vyleesi is ...

Vyleesi is approved for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes markeddistress or ...

In the United States, two drugs have been approved to treat female sexual interest/arousal disorder (FSIAD): Vyleesi (bremelanotide) and Addyi (flibanserin). Some people may refer to these as “Viagra ...

The First FDA-Approved As-Needed Treatment for Premenopausal Women Experiencing Low Sexual Desire and Associated Distress Now Available to Patients WALTHAM, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- ...

The RECONNECT Studies Demonstrated a Clinically Meaningful and Statistically Significant Improvement in the Co-Primary Endpoints of Desire and Associated Distress WALTHAM, Mass., Oct. 11, 2019 (GLOBE ...